INOVIQ LTD. (EGQ0) - Total Assets
Based on the latest financial reports, INOVIQ LTD. (EGQ0) holds total assets worth €21.71 Million EUR (≈ $25.38 Million USD) as of June 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See EGQ0 equity to assets ratio to measure how much of total assets are equity-financed.
INOVIQ LTD. - Total Assets Trend (2021–2024)
This chart illustrates how INOVIQ LTD.'s total assets have evolved over time, based on quarterly financial data. Check how tangible is INOVIQ LTD.'s equity to evaluate the tangible quality of the company's equity base.
INOVIQ LTD. - Asset Composition Analysis
Current Asset Composition (June 2024)
INOVIQ LTD.'s total assets of €21.71 Million consist of 50.0% current assets and 50.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 42.5% |
| Accounts Receivable | €26.56K | 0.1% |
| Inventory | €17.83K | 0.1% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €9.70 Million | 44.7% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how INOVIQ LTD.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see EGQ0 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: INOVIQ LTD.'s current assets represent 50.0% of total assets in 2024, an increase from 20.0% in 2021.
- Cash Position: Cash and equivalents constituted 42.5% of total assets in 2024, up from 18.7% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 44.0% of total assets, a decrease from 75.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 44.7% of total assets.
INOVIQ LTD. Competitors by Total Assets
Key competitors of INOVIQ LTD. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fleury S.A.
SA:FLRY3
|
Brazil | R$13.33 Billion |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716
|
China | CN¥1.74 Billion |
|
Spectral Med Inc
TO:EDT
|
Canada | CA$8.12 Million |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.17 Million |
|
Genetic Signatures Ltd
AU:GSS
|
Australia | AU$49.04 Million |
|
ALPHAHELIX MOL.DIAGN. SK1
F:4MB
|
Germany | €13.12 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
INOVIQ LTD. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.07 | - | - |
| Quick Ratio | 7.06 | - | - |
| Cash Ratio | 0.00 | - | - |
| Working Capital | €9.32 Million | - | - |
INOVIQ LTD. - Advanced Valuation Insights
This section examines the relationship between INOVIQ LTD.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.85 |
| Latest Market Cap to Assets Ratio | 1.17 |
| Asset Growth Rate (YoY) | 0.9% |
| Total Assets | €21.71 Million |
| Market Capitalization | $25.34 Million USD |
Valuation Analysis
Above Book Valuation: The market values INOVIQ LTD.'s assets above their book value (1.17x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: INOVIQ LTD.'s assets grew by 0.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for INOVIQ LTD. (2021–2024)
The table below shows the annual total assets of INOVIQ LTD. from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-06-30 | €21.71 Million ≈ $25.38 Million |
+0.92% |
| 2023-06-30 | €21.51 Million ≈ $25.15 Million |
-30.12% |
| 2022-06-30 | €30.78 Million ≈ $35.98 Million |
-36.30% |
| 2021-06-30 | €48.32 Million ≈ $56.49 Million |
-- |
About INOVIQ LTD.
INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. It offers non… Read more